Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?

Table 5

Multivariate proportional-hazards regression analysis of cofactors on progression-free survival in glioblastoma patients with conventionally fractionated radiotherapy.

Cofactors	HR	95% CI	value
Karnofsky performance status > 80	0.83	0.45–1.53	0.55
Peripheral versus central	0.52	0.26–1.03	0.27
Biopsy versus surgical resection	0.72	0.32–1.60	0.42
Temozolomide therapy	0.78	0.40–1.54	0.47
Mean IL SVZ dose ≥ 40 Gy	0.52	0.26–1.03	0.06
Mean CL SVZ dose ≥ 30 Gy	0.45	0.20–0.98	0.04

CI: confidence interval; HR: hazard ratio; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; Gy: gray.